Introduction
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder marked by the accumulation of undifferentiated myeloid blasts. FLT-3 is one of the most commonly mutated genes in AML. Approximately 30% of AML patients have acquired mutations in the FLT-3 gene, comprising either FLT-3 internal tandem duplication (FLT-3/ITD) mutations (24%) or FLT-3 activation loop mutations (7%). 1 Younger patients with AML have a high complete remission rate, but relapses occur in approximately 50% of cases overall and this figure rises to 70% in patients with FLT3/ITDs. 2, 3 AML is thought to arise from a continuously replenishing rare and functionally distinct leukaemic stem and progenitor cell (LSPC) population characterized by its capacity of self-renewal and generation of leukaemic progenitors. [4] [5] [6] [7] In AML, as in normal haematopoiesis, self-renewal capacity has been identified within the phenotypically immature CD34 þ CD38À subset. 5 To emphasize the clinical relevance of this phenotypically-defined subset, it has been shown that the CD34 þ CD38À LSPC burden at diagnosis correlates with minimal residual disease frequency and poor overall survival in AML. 8 The most common difference between normal and leukaemic CD34 þ CD38À cells lies with the expression of the IL-3-a receptor (CD123) in the latter but not the former. 8, 9 The bone marrow microenvironment provides a highly favourable site for the growth, differentiation and survival of haematopoietic cells. Bone marrow stroma provides adhesion receptors, secreted extracellular matrix and both secreted and membrane bound haematopoietic cytokines. 10, 11 Expression of cell adhesion and cytokine receptors by AML cells has been associated with relapse, supporting the notion that it is not just the leukaemia cells themselves but interactions with their microenvironment that underpin cell survival. 12 Notably, adhesion of primary AML cells to fibronectin mediated by the adhesion receptor VLA-4 promotes in vitro chemoresistance, and VLA-4 overexpression is a prognostic factor for relapse in AML. 13 Cytokines that interact with cell surface receptors, initiating signalling cascades that promote cell growth and division whilst inhibiting the pathways of apoptotic cell death, are also likely to be crucial.
14 Several studies have reported optimized combinations of cytokines capable of supporting the in vitro growth of AML cells. [15] [16] [17] Hatfield et al. 18 reported the production of IL-3 from microvascular endothelium of bone marrow resulting in the proliferation and inhibition of apoptosis of AML blasts. Bone marrow stromal cells also produce IL-6 and stem cell factor (SCF). 11 However, there has been little research emphasis on cytokines which promote survival in the absence of growthFa factor which may be important in the setting of chemoresistance and minimal residual disease. In this context Ang-1, the ligand for receptor Tie-2, has been shown to maintain the survival and quiescence of normal haematopoietic progenitor cells. 19 Thus, in the present study an in vitro system featuring some of the constituents of the bone marrow microenvironment, namely fibronectin, IL-3, IL-6, SCF and Ang-1 were used, and we provide evidence that this cocktail supports survival but not expansion. The true bone marrow microenvironment is complex, and therefore we have used the term 'niche-like' condition to describe the minimal, defined in vitro conditions used to maintain LSPC in this study.
FLT3 inhibitors such as CEP-701 and PKC412 are under investigation for the treatment of AML patients with FLT3 mutations. Clinical results with these as single agents have shown some partial responses with reduction in circulating blasts, but not in marrow blasts. 20, 21 Although it has been shown that FLT3/ITDs are present in the CD34 þ CD38À compartment of AML blast samples, 22 the lack of major in vivo response to FLT3 inhibitors points to the need to evaluate the effect of bone marrow niche conditions and of the LSPC phenotype on response to FLT3 inhibition. In this study, we have optimized an in vitro chemosensitivity assay to model minimal residual disease, taking into account LSPC as well as microenvironment. We used this assay to study in vitro chemoresistance to the drug Ara-C and to the FLT3 inhibitor AG1296. AG1296 is known to be selectively toxic in vitro to blasts from patients with FLT3/ITDs. [23] [24] [25] Materials and methods
Cell samples
Blood or bone marrow samples were obtained after written informed consent from AML patients and healthy stem cell donors. Use of these samples was approved by the appropriate Ethics Committees. Mononuclear cells were isolated using a standard density gradient/centrifugation method with Histopaque and red blood cells depleted from the sample using ammonium chloride. Samples from normal donors were enriched using magnetic separation of cells incubated with anti-CD34-coated beads (Minimacs).
Materials
Recombinant cytokines were obtained from R&D Systems (Abingdon, UK). AG1296, AG490, Wortmannin and U0126 were from Calbiochem (Nottingham, UK). Antibodies were from Becton Dickinson (Cowley, UK). Minimacs beads were from Miltenyi Biotec (Bisley, UK). All remaining reagents were purchased from Sigma (Poole, UK).
Cell culture
Half the wells of a 96-flat-bottom-well plate were coated with fibronectin (20 mg/ml), and the other half were coated with bovine serum albumin (BSA at 2.5 mg/ml). The plate was then incubated at 4 1C overnight and rinsed twice with PBS to remove unbound proteins. Fresh or cryopreserved AML cells were cultured at 10 6 /ml for 48 h, in triplicate, under the conditions specified in the results section. Cells were cultured in serum-free medium consisting of Iscove's modified Dulbecco medium supplemented with 200 mg/ml transferrin, 10 mg/ml insulin, 1% L-glutamine, 2% bovine serum albumin and 10 À4 M mercaptoethanol. For maintenance of the LSPC phenotype in 48 h culture, we treated six AML samples in serum-free medium with immobilized fibronectin along with combination of cytokines IL-3 (20 ng/ml), IL-6 (20 ng/ml), SCF (50 ng/ml) and Ang-1 (300 ng/ml). For the chemosensitivity assays, AG1296 (15 mM), Ara-C (500 ng/ml), AG490 (30 mM), Wortmannin (0.3 mM) and U0126 (1 mM) were used.
Flow cytometric enumeration of LSPC and bulk AML cells
In this study, we looked at the LSPC population (that is, CD34 þ , CD38
À and CD123 þ ) at the start of the assay (t ¼ 0 h) and after in vitro culture (t ¼ 48 h). As shown in Figure 1 , two flow cytometric analyses were used in parallel for the analysis of LSPC survival. One assay allowed reproducible measurement of the concentration of viable cells at the end of the experiment and the second assay allowed the determination of the percentage of LSPC within the viable population. For analysis 1, viability and concentration were measured by incubating cells with 10 mg/ml 7-amino-actinomycin D (7-AAD) and fixed CD45 stained normal mononuclear cells (FSC) as internal standard as described previously. 26 For analysis 2 (phenotype and viability), 90 ml of cultured cells were incubated with 5 ml each of CD34 FITC (fluorescein isothiocyanate), CD38 APC, CD123 PE (or isotype controls) and with 7-AAD (Figure 1iii -v). From these 2 analyses we calculated the concentration of LSPC from the proportion of CD34 þ CD38ÀCD123 þ viable cells.
CD123 fluorescence intensity measurements
Following preliminary antibody dilution studies (data not shown), samples were labeled with PE-conjugated CD123 antibodies and with CD34 FITC, CD45PerCP and CD38 APC. For fluorescence quantitation, control tubes were set up substituting isotype-and-concentration-matched non-specific PE conjugated antibodies for the test antibodies. A CD45-intermediate/side scatter low blast gate was used. CD123 fluorescence intensity was measured in CD34 þ CD38À leukaemic samples and compared to those of normal donor samples. Fluorescence intensity was expressed as a ratio of test to isotype control antibody fluorescence. To ensure consistent test: control fluorescence over time, instrument performance was monitored using the Becton Dickinson Calibrite/Autocomp system, and fluorescence ratios were calculated from standard curves obtained using Dako Fluorospheres. Thus, day-to-day variations in cytometer performance are unlikely to have a major impact on the fluorescence ratios.
Counting of rare events and derivation of 10% coefficient of variation
As the incidence of CD34 þ CD38À cells in a blast sample can be very low, we adopted a consistent strategy to maintain data reliability. Briefly, if N events are counted, of which the proportion of positive events is P, the expected s.d. of a proportion size P in sample size N ¼ O{P(1ÀP)/N}. 27 However, when events are rare, the binomial variance P(1ÀP)/N approximates P/N. The coefficient of variation (CV), which is defined as s.d. Â 100%/mean becomes O{P/N} Â 100%/P. We set the acceptable coefficient of variation to 10%, such that the final equation is NP ¼ 100. Therefore, to maintain a consistent CV of 10% or better, we only allowed analysis of data that included at least 100 CD34 þ CD38À events (after subtraction of false positive from the isotype control tubes).
FLT3 status
FLT3/ITDs were analysed by previously described methods. 28 ITD mutations were confirmed by analysis on a 3130 Genetic Analyser (Applied Biosystems, Warrington, UK).
Statistics
Statistical analyses were performed using SPSS software. Nonparametric analysis was used for significance testing.
Results

Surface expression of CD123 on leukaemic CD34 þ CD38À cells
To establish the nature (normal or leukaemic) of the CD34 þ CD38À mononuclear cell compartment, we compared the frequency of CD34 þ CD38À cells and their expression of CD123, reported to be elevated on leukaemic stem cells compared with their normal counterparts. 9 CD123 mean fluorescence intensity (MFI) measurements of leukaemic and 29 LAPs were found in all three cases (data not shown).
We wanted to be able to use samples from all AML patients in our in vitro model. However, our calculated maximum coefficient of variation meant that we could only include samples where at least 100 cells (out of 100 000 counted) were LSPC. In an attempt to use samples with a low frequency of CD34 þ CD38À cells, five additional samples with starting concentrations o0.1% CD34 þ CD38À cells were enriched with CD34-coated magnetic beads before phenotyping. In all five cases the CD123 MFI was below the cutoff point (MFI range 1.3-12. 2), such that we had no evidence that the CD34 þ CD38À cells were leukaemic. The yield of sorted cells was too low for CD34 þ CD38À LAP analysis, so we also could not confirm that these cells were normal. However, an assumption of normality would accord with evidence established on the normal nature of total CD34 þ cells where their frequency in an AML sample is low. 30 We also measured Tie-2 expression on CD34 þ CD38À AML cells, but did not observe overexpression of Tie-2 in AML compared to donor cells.
Maintenance of LSPC in in vitro culture
To investigate the possibility of maintaining LSPC in culture for 48 h without differentiation (that is, loss of phenotype), we compared various culture conditions. Samples were highly heterogeneous, such that no combinations of factors assayed were significantly better at LSPC maintenance than others (data not shown). However, using serum free medium, immobilized fibronectin, IL-3, IL-6, SCF and Ang-1 we were able to maintain the LSPC population for 48 h culture: n ¼ 7; median LSPC concentration at the start of the assay 3.4 Â 10 4 /ml (range 2.3-34 Â 10 4 /ml); median LSPC concentration at 48 h 3.0 Â 10 4 /ml (range 1-57 Â 10 4 /ml) (Figure 2a ). In contrast, there was a dramatic 85% (median) loss of LSPC in culture without fibronectin or cytokines: the median concentration at 48 h was 0.5 Â 10 4 /ml (range 0.2-14 Â 10 4 /ml, P ¼ 0.018). In vitro Resistance to FLT3 inhibition by AML stem cells U Mony et al survival of bulk cells was also enhanced by niche-like conditions (P ¼ 0.007, n ¼ 11, Figure 2b ).
In vitro resistance of LSPC to Ara-C and AG1296
As AML is characterized by a high remission rate (that is, reduction in total bone marrow blasts), but relapse in the majority of cases, we wanted to create a model with features of the bone marrow niche in which the microenvironment would protect the LSPC from cytotoxic drugs. The bone marrow niche of mice transplanted with AML has recently been shown to be resistant to Ara-C. 31 To determine whether our in vitro conditions would mimic those in vivo findings we cultured AML cells with and without fibronectin and cytokine support. In cultures of AML cells without fibronectin or cytokine support, the survival of LSPC treated with 500 ng/ml Ara-C increased significantly from a median 10% of control values in cells grown on albumin coated wells to 36% under niche conditions (P ¼ 0.018, Figures 3a-b) .
Next, we examined the effect of the tyrosine kinase inhibitor AG1296 on the survival of bulk cells and of LSPC cultured under these defined conditions from nine AML samples with FLT3/ ITDs (Table 1 ). In cells cultured without fibronectin or cytokine support, 450% kill of bulk cells was achieved in 3/9 samples at an AG1296 dose of 15 mM. In four out of nine samples there was between 10 and 50% kill, and two samples were resistant (Table 1) . Of the seven samples that were sensitive at the bulk cell level without microenvironmental support, four samples showed an increase in percentage cell survival under 'nichelike' conditions compared to unsupported cell survival (P ¼ 0.073). We then analyzed six of the AML samples with FLT3/ITDs to determine the response of the LSPC subset to AG1296 under 'niche-like' conditions. Under these conditions, the LSPC population was completely resistant to AG1296 in 5/6 cases (samples 1, 3, 4, 5 and 8 in Table 1 ). In these samples AG1296-treated LSPC survival was enhanced rather than diminished compared to untreated LSPCs ( Table 1 ). The increase in AG1296-treated LSPC survival under niche support compared to unsupported cell survival was statistically significant (P ¼ 0.012). Figure 4 shows FACS (fluorescence-activated cell sorting) plots of surviving AG1296-treated LSPC cultured with and without niche-like conditions.
As a control for the previous experiment, we wanted to ensure that in the defined 'niche-like' condition LSPCs can be targeted by other signalling inhibitors. Seven AML samples were treated with inhibitors of MAPK (U0126), JAK-STAT (AG490) and PI3K (Wortmannin) and compared to appropriate DMSO (dimethyl sulphoxide) controls (Figures 5a-c) . After 48 h, the percentage There was an even greater cell kill of the LSPC subset after 48 h treatment with the same inhibitors, where a cell kill of 30.53 ± 7.02, 26.24±4.5 and 24.54±4.88% was achieved by U0126, AG490 and Wortmannin, respectively. These experiments showed clearly that it is possible to kill LSPC using signalling inhibitors despite 'niche-like' conditions. However, the relative toxicities of these agents should not be inferred from this experiment, which was performed with a single dose of each agent.
Discussion
There was a considerable emphasis on methodology in this study, which will be discussed first. We have presented a system where the chemosensitivity of LSPC from AML samples can be detected in as few as 100 viable cells. The methodology allows quick screening of chemotherapeutic drugs and may, therefore, be a useful prelude to the rigorous demands of in vivo experiments. As well as the identification of LSPC by phenotyping, advantages of a flow cytometric screening assay to detect LSPC chemosensitivity include speed (that is, a result at 48 h) and reproducibility (that is, a viable cell count based on several thousand events). Moreover, assessing bulk cells and LSPC chemosensitivity on the same patient sample is undertaken in parallel, so the two compartments can be compared.
A potential problem in this type of analysis is distinguishing normal from leukaemic CD34 þ CD38À cells. We have built on previous reports of CD123 positivity in LSPC 8, 9, 32 by measuring CD123 expression levels on a quantitative scale and have established a cutoff point between normal and leukaemic stem and progenitor cells. For the minority of samples with low CD123 on CD34 þ CD38À cells we found the LSPC LAP assay reported by van Rhenen et al. 29 a useful way of confirming the leukaemic nature of the subset. The 3/17 samples in our cohort with a CD34 þ CD38ÀCD123 lowLAP þ subset were not used in our chemosensitivity analysis, but in principle it would be straightforward to incorporate alternative LAP markers into the chemosensitivity assay. However, we were unable to confirm the leukaemic nature of LSPC when these constituted o0.1% of the starting blast population.
Our defined 'niche-like' microenvironment, consisting of serum free medium, immobilized fibronectin, IL-3, IL-6, SCF and Ang-1, is able to support and maintain the LSPC population in culture without loss of phenotype for at least 48 h (Figure 2a ). An important caveat to our assay system is that AML cells themselves secrete cytokines, including IL-3, IL-6, and SCF 33, 34 to variable extents, and therefore it is not possible to totally standardize the profile of survival factors to which the cells are exposed.
In this study, we have shown that factors found in the bone marrow microenvironment interact with LSPC in vitro to induce resistance to Ara-C and AG1296. Ex vivo, leukaemic stem cells Table 1 . LSPC, leukaemic stem and progenitor cells.
Resistance to FLT3 inhibition by AML stem cells U Mony et al are reported to be quiescent, which may account for their escape from the cytotoxicity of the S-phase agent Ara-C. 35 However, this in vitro quiescence is short-lived, probably due to autocrine or paracrine stimulation 33 and we documented considerable toxicity at 48 h. We also found a decrease in the percentage kill of LSPC under our 'niche-like' conditions compared to unsupported suspension culture, suggesting that it is not the LSPC alone, but their interaction with a supportive niche, that mediates resistance to Ara-C, in keeping with the in vivo findings of Ishikawa et al.
31
It has been reported that FLT3 mutations comprise a major genetic mutation in AML and are associated with poor prognosis. 36 Therefore, the FLT3 receptor represents a therapeutic target in AML. In this study, we have used AG1296, which is well characterized as a FLT3 inhibitor [23] [24] [25] and found that LSPC with 'niche-like' support were completely resistant in 5/6 samples assessed. This is in sharp contrast to FLT3ITD bulk cells grown without niche support. This finding may underpin the clinical observation that the FLT3 inhibitors CEP-701 and PKC412 deplete circulating blasts but are less effective against marrow blasts. 20, 21 Moreover, the enhanced survival of AG1296-treated LSPC compared with untreated controls suggests that alternative survival pathways are activated to compensate for those inhibited by AG1296. This phenomenon is under active investigation in our laboratory. We have, however, managed to target the LSPC subset under the same defined 'niche-like' conditions that were shown to be highly resistant to Ara-C and AG1296. This was achieved when using three separate signalling inhibitors that target the major signalling pathways involved in cell survival and proliferation, namely the JAK-STAT, PI3K and MAPK pathways.
Conclusion
We have demonstrated that defined 'niche-like' conditions promote the in vitro survival of LSPC from AML samples, and have shown that, under these conditions, 5/6 LSPC subsets from samples with FLT3/ITDs were completely resistant to AG1296. Although pharmacological FLT3 inhibitors may be more effective than AG1296, we suggest that it would be useful to assay the effects of such agents on LSPC under 'niche-like' conditions, as the current study does not provide a rationale for the clinical use of single agent FLT3 inhibitors to target residual LSPC after chemotherapy. 
